NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/08/2025
Back to search
Official data from USPTO
SLOREL
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
42
Latest update
07/08/2025
Trademark type
Word
Nice classes
5
Filing date
09/15/2022
Registration date
07/08/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/08/2025
Last transaction
07/08/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
03
Owner location
Gyeonggi-do, KR
Examiner
SAXTON, EVELYN H
Law office
M30
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
CG Bio Co., Ltd.
Representatives
Caroline E. Bryce SHERIDAN ROSS P.C.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Surgical implants comprised of living tissues for guided tissue regeneration; implants comprising living tissue; implantable materials for use in guided tissue regeneration in the nature of implants comprising living tissue; Surgical implants comprised of living tissues used in transplantsvascular grafts being living tissue and human allograft tissue; surgical implants comprised of living tissues; human allograft tissue; bone void fillers comprised of living tissues; Stem cells for medical purposessurgical implants grown from stem cells; pharmaceutical preparations for use in tissue transplantation; pharmaceutical preparations for tissue regeneration; medicines for human purposespharmaceutical preparations for the treatment of musculo-skeletal disorders; medicines for human purposesa drug delivery system comprising liquidspowderstablets or capsules for the continuous release of a wide variety of therapeutic agentspharmaceutical preparations for the treatment of musculo-skeletal disorders; drugs for medical purposesdrugs for use in bioregenerative proceduresdrugs for use for regenerative purposedrugs for use to assist with artificial bone growthdrugs for use in accelerating bone formationdrugs for use to stimulate new bone formation; pharmaceutical agents affecting sensory organs; pharmaceutical preparations for the prevention of diseases of the musculo- skeletal system; pharmaceutical preparations for the treatment of Musculo-skeletal disorders; cellular function activating agents for medical purposes; pharmaceutical preparations for use in organ transplantation; biological tissue cultures for medical purposes; drug delivery agents in the form of liquidpowderstablets and capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of dissolvable films added to bone substitutes that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films for use in bioregenerative procedures that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films that provide sustained release of drugs for use with implants and bone substitutes that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of drug delivery compounds that facilitate sustained or extended release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of dissolvable films with controlled timing and rate of drug release that facilitate the delivery of pharmaceutical preparations; medicines for human usenamely pharmaceutical preparations for the treatment of musculo-skeletal disorders featuring controlled timing and rate of release; medical bone graft substitutebiological tissue bone grafts; medical bone graft materialsbone fillers consisting of living materials; medical bone graft materials with drug release function being bone growth media consisting of biological materials for medical bone graft purposes with drug release function; medical bone graft materialsbiological bone tissue intended for subsequent implantation in a bone graft with drug release functionthat provide sustained release of drugs for use with implants and bone substitutes; medical bone graft materials being biological bone tissue intended for subsequent implantation with drug release function that are sold filled with pharmaceutical preparationsbiological growth factorsused with implants and bone substitutes; medical bone graft materials being biological bone tissue intended for subsequent implantation with drug release function that are sold filled with pharmaceutical preparationsantibioticsused with implants and bone substitutes
Publications
History of USPTO decisions and trademark events.
42 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
07/08/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/20/2025
PUBO
PUBLISHED FOR OPPOSITION
05/20/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/14/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/17/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/14/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/14/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/14/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/08/2025
GNRT
NON-FINAL ACTION E-MAILED
01/08/2025
CNRT
NON-FINAL ACTION WRITTEN
01/08/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
12/17/2024
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
12/12/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/12/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/12/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/12/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/12/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/12/2024
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
11/06/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
11/06/2024
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
11/06/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/06/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/06/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/06/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/06/2024
ALIE
ASSIGNED TO LIE
11/05/2024
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
08/13/2024
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
03/12/2024
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
01/17/2024
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
06/16/2023
GNSL
LETTER OF SUSPENSION E-MAILED
06/16/2023
CNSL
SUSPENSION LETTER WRITTEN
06/16/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/12/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/12/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/12/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/14/2023
GNRT
NON-FINAL ACTION E-MAILED
04/14/2023
CNRT
NON-FINAL ACTION WRITTEN
04/14/2023
DOCK
ASSIGNED TO EXAMINER
03/14/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/01/2022
NWAP
NEW APPLICATION ENTERED
09/19/2022
Continuous trademark protection
Get notified about every new filing that threatens SLOREL or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.